GSK plc (GSK) vs State Street SPDR S&P 500 ETF (SPY)
Over the past 10 years, GSK lagged SPY — 7.50% vs 15.54% annualized total return (price plus dividends).
A side-by-side comparison of GSK plc and State Street SPDR S&P 500 ETF across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 27, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
Total return — GSK vs SPY
growth of $100 · last 30yMetrics side by side
Did GSK beat SPY?
Over the past 10 years, GSK lagged SPY — 7.50% vs 15.54% annualized total return (price plus dividends).
Total return (annualized)
| Metric | GSK | SPY |
|---|---|---|
| Total return (1Y) | 41.39%● | 21.30% |
| Total return CAGR (3Y) | 17.67% | 20.87%● |
| Total return CAGR (5Y) | 10.18% | 12.98%● |
| Total return CAGR (10Y) | 7.50% | 15.54%● |
SPY is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has GSK beaten SPY?
- Over the past 10 years, GSK lagged SPY — 7.50% vs 15.54% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 27, 2026.